FAP and neoplasm: Finally worth mentioning is the more recent development of radiopharmaceuticals that target the tumour microenvironment in particular cancer-associated fibroblasts (CAFs) expressing fibroblast-activating protein (FAP), tumour-associated macrophages (TAMs), and tumour angiogenesis.